

# Index

<b>1. Cancer Epidemiology. Tumor Biology. Cancer Genomics. Therapeutic Approach to Cancer</b>	<b>1</b>
1.1. Cancer Epidemiology	1
1.2. Tumor Biology	2
1.3. Cancer Genomics	3
1.4. Therapeutic Approach to Cancer	8
1.5. Cancer Medicine	9
1.6. Cancer and Society	11
<b>2. Definition and Classification of Cancer Therapeutics-Related Cardiac Toxicity and Dysfunction. Mechanisms of Cardiac Toxicity</b>	<b>15</b>
2.1. Introduction	15
2.2. Definition of Cancer Therapeutics-Related Cardiac Dysfunction	15
2.3. Classification of Cancer Therapeutics-Related Cardiac Dysfunction	17
2.4. Mechanisms of Cardiac Toxicity	18
2.5. Conclusions	21
<b>3. Cardiac Dysfunction Secondary to Anthracyclines</b>	<b>25</b>
3.1. Introduction	25
3.2. Anthracyclines in Oncology	25
3.3. Definition of Anthracycline-induced Cardiomyopathy	26
3.4. Risk Factors for Anthracycline-induced Cardiomyopathy	26
3.5. Pathology of Chronic Anthracycline-induced Cardiomyopathy	27
3.6. Selection of Patients for Anthracycline Therapy	27
3.7. Early Detection of Anthracycline-induced Cardiomyopathy	28
3.8. Diagnosis of Anthracycline-induced Cardiomyopathy	28
3.9. Prevention of Anthracycline-induced Cardiomyopathy	29
3.10. Treatment of Anthracycline-induced Cardiomyopathy	29
3.11. Other Chemotherapy Agents	29
3.12. Conclusions	30
<b>4. Cancer Therapeutics-Related Cardiac Dysfunction Secondary to Tyrosine-Kinase Inhibitors: Monoclonal Antibodies and Small Molecule Tyrosine-Kinase Inhibitors</b>	<b>33</b>
4.1. Introduction	33
4.2. Monoclonal Antibodies	34
4.3. Small Molecule Tyrosine-Kinase Inhibitors	37
4.4. Conclusions	39
<b>5. Vascular Implications in Cancer Dissemination</b>	<b>43</b>
5.1. Angiogenesis: a Critical Process for Tumor Growth, Progression and Dissemination	43
5.2. Critical Players in Blood Vessel Maturation and Stabilization	44
5.3. Lymphangiogenesis	46
5.4. Anti-angiogenic Approaches in Cancer	47
5.5. Conclusions	49
<b>6. Radiation-Induced Heart Disease</b>	<b>57</b>
6.1. Introduction	57
6.2. Frequency and Prevalence	57
6.3. Pathophysiology	58
6.4. Risk Factors	58
6.5. Challenges in Defining Volumes	59
6.6. Cardiotoxicity and Breast Cancer	59
6.7. Cardiotoxicity and Other Thoracic Tumors	65
6.8. Cardiotoxicity and Hodgkin Lymphoma	65
<b>7. Use of Biomarkers in the Early Detection/ Risk Stratification of Subclinical Left Ventricular Dysfunction in Patients Undergoing Cancer Therapy</b>	<b>73</b>
7.1. The Role of Biomarkers as Diagnostic and Prognostic Tools in Cancer Therapy Associated Cardiotoxicity	73
7.2. Troponins	73
7.3. Brain-type Natriuretic Peptide	80
7.4. Emerging Biomarkers in Assessing Cancer Therapy Induced Cardiotoxicity	81
7.5. The Role of Biomarkers as Screening Tools to Aid in the Prevention of Cardiotoxicity	86

7.6. An Integrated Approach to Multiple Biomarkers and Imaging	86	12.1. Introduction	143
7.7. Conclusions	87	12.2. Incidence	143
<b>8. Imaging Techniques in the Detection of Cancer Therapeutics-Related Cardiac Dysfunction: Standard Echocardiography</b>	<b>91</b>	12.3. Etiology and Pathophysiology	144
8.1. Introduction	91	12.4. Suggested Algorithm for Evaluation of Arterial Ischemic Events in Patients with Underlying Malignancy	149
8.2. Left Ventricular Ejection Fraction	91	12.5. Management	149
8.3. Diastolic Function	95	12.6. Outcome	150
8.4. Right Ventricular Function	96	12.7. Conclusions	151
8.5. Special Considerations in Radiotherapy	97	<b>13. Thrombosis, Coagulation and Cancer</b>	<b>157</b>
8.6. Echocardiography Monitoring Guidelines for Cancer Therapeutics-Related Cardiotoxicity	98	13.1. Introduction	157
8.7. Conclusion	101	13.2. Causes Favoring Thrombotic Phenomena in Cancer Patients	158
<b>9. Imaging Techniques in the Detection of Sub-Clinical Left Ventricle Dysfunction</b>	<b>107</b>	13.3. Why do Cancer Cells Promote Platelet Activation?	158
9.1. Introduction	107	13.4. Mechanisms Associated with Venous Thromboembolism	159
9.2. Strain Imaging	107	13.5. Biomarkers to Predict the Risk of Thromboembolic Events in Cancer Patients	160
9.3. Left Ventricular Torsion and Twist	115	13.6. Pharmacologic Prevention of Thrombo-coagulating Events in Cancer Patients	161
9.4. Conclusions	115	13.7. Genetic Alterations Related to Cancer and Risk of Thromboembolic Events	161
<b>10. Imaging Techniques in the Detection of Cancer Therapeutics-Related Cardiac Toxicity</b>	<b>117</b>	<b>14. Management of Cardiac Insufficiency and Heart Failure in Cancer Patients</b>	<b>165</b>
10.1. Introduction	117	14.1. Introduction	165
10.2. Equilibrium Radionuclide Angiography	117	14.2. Detection of Heart Failure in Cancer Patients	165
10.3. Cardiac Magnetic Resonance Imaging	120	14.3. Adjustments to Chemotherapy in Patients with Heart Failure or Left Ventricular Dysfunction	166
<b>11. Myocardial Ischemia and Acute Coronary Syndrome in Cancer Patients</b>	<b>131</b>	14.4. Hypertension as a Precursor to Heart Failure	168
11.1. Introduction	131	14.5. Survivors of Cancer Therapy (Post-treatment) and Risk of Heart Failure	168
11.2. Risk Factors and Pathophysiology	131	14.6. Conclusions	169
11.3. Diagnostic Criteria and Diagnostic Testing for Myocardial Ischemia and Acute Coronary Syndromes	134	<b>15. Arrhythmias and Cardiac Devices in Oncology Patients</b>	<b>173</b>
11.4. Treatment of Acute Coronary Syndromes in Cancer Patients	136	15.1. Introduction	173
<b>12. Peripheral Arterial Disease in Cancer Patients</b>	<b>143</b>	15.2. Cardiac Arrhythmias	173
		15.3. Cardiac Electrophysiologic Study	179

15.4. Cardiac Devices	179	20.4. Treatment of Dyslipidemia in Cancer Patients	236
15.5. Conclusions	182	20.5. Diabetes Mellitus and Cancer	236
<b>16. Other Complications: Myocarditis, Pericardial Disease, Valvular Heart Disease</b>	<b>185</b>	20.6. Conclusions	238
16.1. Introduction	185	<b>21. Cardio-protection: Early Detection and Treatment of Subclinical Left Ventricle Dysfunction</b>	<b>241</b>
16.2. Mechanisms of Cancer Therapy-Induced Cardiotoxicity	185	21.1. Background	241
16.3. Myocarditis	186	21.2. Potential Targets	242
16.4. Pericardial Disease	186	21.3. Protective Therapies	243
16.5. Valve Disease	187	21.4. Potential Strategies	245
16.6. Conclusions	188	21.5. Conclusion: Need for Evidence	246
<b>17. Systemic Hypertension and Cancer</b>	<b>191</b>	<b>22. Surveillance of Cardiotoxicity during Chemotherapy and Radiotherapy</b>	<b>251</b>
17.1. Introduction	191	22.1. Introduction. Definition of Cardiovascular Toxicity of Cancer Therapy	251
17.2. Antihypertensive Therapy and Cancer Risk	191	22.2. Why Is There a Need for Surveillance of Cardiotoxicity During Chemotherapy and Radiotherapy?	252
17.3. Cancer Therapy Causes Hypertension	194	22.3. Risk Stratification: Definition of the Populations that Require Surveillance During Chemotherapy and Radiotherapy	253
<b>18. Cardiac Tumors: Presentation, Imaging and Management Options</b>	<b>201</b>	22.4. How to Monitor Heart Function during Chemotherapy and Radiotherapy. Follow-up Tools	255
18.1. Introduction	201	22.5. Preventive Measures and Early Cardiotoxicity Treatment	260
18.2. Epidemiology	201	22.6. Defining the Timescale for an Appropriate Surveillance	261
18.3. Clinical presentation	203	<b>23. Long-term Follow-up of Patients Treated with Chemotherapy/Radiotherapy</b>	<b>267</b>
18.4. Diagnosis	205	23.1. Introduction. Magnitude of the Problem	267
18.5. Pathology and Prognosis	207	23.2. Acute <i>versus</i> Chronic Chemotherapeutic Cardiotoxicity	267
18.6. Treatment	208	23.3. Long-Term Chemotherapy-Related Toxicity: Epidemiology	268
<b>19. Prevention of Cardiotoxicity: New Strategies in the Management of Cancer Therapeutics</b>	<b>215</b>	23.4. Long-term Monitoring of Patients Treated for Cancer	271
19.1. Introduction	215	23.5. Cardiotoxicity and Radiotherapy in Cancer Treatment	273
19.2. Left Ventricular Dysfunction	215		
19.3. QT Interval Prolongation	221		
19.4. Venous Thrombosis	222		
19.5. Ischemia	224		
<b>20. Treatment of Cardiovascular Risk Factors in Cancer Patients</b>	<b>233</b>		
20.1. Introduction	233		
20.2. Lifestyle Recommendations in Cancer Patients	233		
20.3. Management of Hypertension in Cancer Patients	234		



23.6. Risk Factors for Radiotherapy-Related Cardiotoxicity. Basic Guidelines for Monitoring .....	276	24.3. Organization of Cardio-Oncology Multidisciplinary Teams .....	282
<b>24. Organization and Implementation of a Cardio-Oncology Center .....</b>	<b>281</b>	24.4. Quality indicators .....	285
24.1. Introduction .....	281	24.5. Cardio-Oncology in a <i>Cancer Survivorship Program</i> .....	286
24.2. Definition of Cardio-Oncology Multidisciplinary Teams .....	281	24.6. Conclusions .....	288
		<b>Instructions for the use of Augmented Reality .....</b>	<b>290</b>

# Index

<b>1. Chronic Anthracycline-Induced Cardiotoxicity</b>	<b>2</b>
1.1. Case Presentation	2
1.2. Discussion	5
1.3. Conclusions	5
<b>2. Subacute Anthracycline-Induced Cardiotoxicity</b>	<b>6</b>
2.1. Case Presentation	6
2.2. Discussion	10
2.3. Conclusions	11
<b>3. Cardiogenic Shock after Chemotherapy Treatment</b>	<b>12</b>
3.1. Case Presentation	12
3.2. Discussion	15
3.3. Conclusions	15
<b>4. Acute Pericarditis during Radiation Therapy</b>	<b>16</b>
4.1. Case Presentation	16
4.2. Discussion	18
4.3. Conclusions	18
<b>5. Valvulopathy Induced by Radiotherapy</b>	<b>20</b>
5.1. Case Presentation	20
5.2. Discussion	22
5.3. Conclusions	22
<b>6. Chest Pain in a Radiotherapy Patient</b>	<b>24</b>
6.1. Case Presentation	24
6.2. Discussion	26
6.3. Conclusions	26
<b>7. Subclinical Left Ventricular Dysfunction after Chemotherapy Treatment</b>	<b>28</b>
7.1. Case Presentation	28
7.2. Discussion	31
7.3. Conclusions	32
<b>8. Chemotherapy and Chest Radiation as Risk Factor for Cardiotoxicity: How to Manage this High Risk Population</b>	<b>34</b>
8.1. Case Presentation	34
8.2. Discussion	38
8.3. Conclusions	38
<b>9. Previous Cardiovascular Disease as a Risk Factor of Cardiotoxicity</b>	<b>40</b>
9.1. Case Presentation	40
9.2. Discussion	42
9.3. Conclusions	42
<b>10. Use of Cardiac Biomarkers in the Follow-up of an Oncologic Patient</b>	<b>44</b>
10.1. Case Presentation	44
10.2. Discussion	47
10.3. Conclusions	47
<b>11. Development of Left Ventricular Dysfunction after Rechallenge with Cardiotoxic Drugs</b>	<b>48</b>
11.1. Case Presentation	48
11.2. Discussion	51
11.3. Conclusions	51
<b>12. Symptomatic Sinus Tachycardia during Chemotherapy; Association with Overall Cardiac Mortality</b>	<b>52</b>
12.1. Case Presentation	52
12.2. Discussion	55
12.3. Conclusions	55
<b>13. Cardiotoxicity Monitorization during Chemotherapy</b>	<b>56</b>
13.1. Case Presentation	56
13.2. Discussion	59
13.3. Conclusions	59

<b>14. Transient Anthracycline-Induced Left Ventricular Dysfunction</b>	<b>60</b>	<b>18. Secondary Cardiac Tumor after Osteosarcoma</b>	<b>78</b>
14.1. Case Presentation	60	18.1. Case Presentation	78
14.2. Discussion	64	18.2. Discussion	82
14.3. Conclusions	65	18.3. Conclusions	82
<b>15. Trastuzumab-Induced Cardiotoxicity</b>	<b>66</b>	<b>19. Pulmonary Artery Sarcoma Mimicking a Pulmonary Embolism</b>	<b>84</b>
15.1. Case Presentation	66	19.1. Case Presentation	84
15.2. Discussion	68	19.2. Discussion	87
15.3. Conclusions	68	19.3. Conclusions	87
<b>16. Shortness of Breath in a Hodgkin Lymphoma Patient</b>	<b>70</b>	<b>20. Atrial Fibrillation and Cancer</b>	<b>88</b>
16.1. Case Presentation	70	20.1. Case Presentation	88
16.2. Discussion	72	20.2. Discussion	90
16.3. Conclusions	73	20.3. Conclusions	90
<b>17. Right Atrial Mass in a Breast Cancer Patient</b>	<b>74</b>	<b>Instructions for the use of Augmented Reality</b>	<b>91</b>
17.1. Case Presentation	74		
17.2. Discussion	76		
17.3. Conclusions	76		